BRAF and metastatic melanoma: Since 2015 it has been approved for the treatment of metastatic melanoma in patients without BRAF mutation regardless of programmed death-ligand 1 (PD-L1) expression proving superiority in terms of overall survival compared to chemotherapy with dacarbazine [8].